Scadden David 4

What Happened David Scadden, a director of Agios Pharmaceuticals (AGIO), shows activity on 2026-06-18 converting/exercising 2,816 derivative units into shares (reported as acquired) and a matching disposition of 2,816 shares (both at $0.00). On the same date he was granted awards totaling 17,877 derivative units (2,927 and 14,950 units), all reported at $0.00. The filings indicate these were awards/restricted stock units and option awards with future vesting dates; no cash consideration was reported.

Key Details

• Transaction date: 2026-06-18 (Form filed 2026-06-23 — filing appears late relative to the 2-business-day Form 4 rule).
• Reported trades: conversion/exercise (M) 2,816 shares acquired @ $0.00; disposition (M) 2,816 shares @ $0.00; grants/awards (A) 2,927 and 14,950 derivative units @ $0.00.
• Total new awards reported: 17,877 units (2,927 + 14,950).
• Total cash reported exchanged: $0.00 for all items.
• Shares owned after the transactions: not provided in the data supplied.
• Footnotes:
  • F1: Each RSU equals a contingent right to one common share.
  • F2: The 2,927 RSUs were originally granted 6/18/2025 and vest in full 6/18/2026; vested shares to be delivered within three business days after vesting.
  • F3: The 14,950 RSUs/options were granted 6/18/2026 and vest in full 6/18/2027; vested shares to be delivered within three business days after vesting.
  • F4: Options granted 6/18/2026 vest 100% on 6/18/2027.
• No 10b5-1 plan or tax-withholding explanation is included in the provided footnotes.

Context

• These transactions are primarily awards and conversions of derivatives (RSUs/options); awards are not purchases and do not by themselves signal a direct purchase-based bullish vote.
• The matching disposition of 2,816 shares reported at $0.00 accompanies the conversion/exercise; the Form does not state the reason (e.g., sale, net settlement, or withholding).
• Because the Form 4 was filed several days after the transaction date, it appears to be late under the standard two-business-day reporting rule, which is worth noting for timeliness-sensitive investors.